Galectin-3 And Phagocyte Function In Severe Asthma
Funder
National Health and Medical Research Council
Funding Amount
$698,084.00
Summary
Asthma, a major chronic inflammatory disease affects more than 2 million Australians. Neutrophilic severe asthma is not responsive to current therapies. We have recently made a significant advance in understanding neutrophilic asthma, reporting low levels of a protein called galectin-3 (gal-3). In this project we will explore the role of gal-3 its effect on the resolution of inflammation. This study will result significantly advance the knowledge of the mechanisms of neutrophilic severe asthma.
G-CSF: A Pathogenic Effector In Chronic Obstructive Pulmonary Disease And Its Comorbidities
Funder
National Health and Medical Research Council
Funding Amount
$1,241,551.00
Summary
Chronic Obstructive Pulmonary Disease (COPD) is an incurable lung disease that is a huge global health burden, and new therapies are urgently needed. We have recently discovered a possible cause of COPD. This single factor also appears to drive other associated medical problems that are the biggest contributors to patient deterioration. Using advanced genetics, biochemistry and molecular methods we are searching for ways to turn our discovery into effective treatments for this fatal disease.
Inflammometry In Stable COPD; A Randomised Controlled Trial (RCT)
Funder
National Health and Medical Research Council
Funding Amount
$743,351.00
Summary
COPD is a common condition associated with many clinical consequences that negatively impact on quality of life. The burden of illness from COPD remains high despite current treatment. There is an urgent need to improve management of COPD and we propose that individualized management targeted to airway and systemic inflammation will do this. This study will examine the effect of targeted anti-inflammatory treatment in patients with COPD and will examine the role of a simple blood test to assess ....COPD is a common condition associated with many clinical consequences that negatively impact on quality of life. The burden of illness from COPD remains high despite current treatment. There is an urgent need to improve management of COPD and we propose that individualized management targeted to airway and systemic inflammation will do this. This study will examine the effect of targeted anti-inflammatory treatment in patients with COPD and will examine the role of a simple blood test to assess and manage COPD.Read moreRead less
Defining Roles Of Innate Lymphoid Cells In Chronic Kidney Disease For Future Therapy
Funder
National Health and Medical Research Council
Funding Amount
$638,825.00
Summary
Chronic kidney disease is a major cause of death and morbidity in Australia. Current strategies that delay progression of kidney disease are limited. Innate lymphoid cells are a newly identified heterogeneous family of immune cells, which have important roles in tissue homeostasis and pathologic inflammation. The central aims of the project are to define the role of innate lymphoid cells in chronic kidney disease, and further to explore their therapeutic potential in kidney disease.
Gamma-Delta Tregs, CD8 Tregs And Selected Natural Tregs To Treat Renal Injury
Funder
National Health and Medical Research Council
Funding Amount
$605,096.00
Summary
Chronic kidney disease (CKD) progresses due to ongoing damage to the kidney. We have identified three types of white cells that can reduce kidney damage in CKD. The first is a unique set of gamma-delta T cells that expand in the kidney and protect against injury. The second is a restricted set of CD8 T cell that can protect against kidney injury. The third are targeted natural regulatory T cells. These studies develop each of these three subsets as potential cellular therapies in CKD.
Targeting Oxidant-dependent Pathways To Treat Skeletal Muscle Wasting In COPD
Funder
National Health and Medical Research Council
Funding Amount
$1,089,054.00
Summary
Chronic Obstructive Pulmonary Disease (COPD) is a major incurable global health burden and is the 4th largest cause of death worldwide. A significant proportion of COPD patients have skeletal muscle wasting and loss of strength which severely impacts on their quality of life and survival. The reason for this is unknown so the aim of this study is to determine how skeletal muscle wasting occurs in COPD and to then develop new medicines to treat skeletal muscle wasting and dysfunction in COPD.
During injury or infection, our body’s immune system protects us by launching inflammation. But uncontrolled inflammation drives common diseases such as cancer, diabetes and Alzheimer’s. This project will reveal how the body deactivates inflammasomes - protein complexes at the heart of inflammation and disease – so we can design better strategies for treating patients with inflammation-driven disease.
Optimising The Therapeutic Efficacy Of Anti-inflammatory Macrophages For Use In Chronic Kidney Diseases
Funder
National Health and Medical Research Council
Funding Amount
$605,096.00
Summary
Chronic kidney disease (CKD) is a major cause of death and morbidity in Australia. Current treatments that are able to delay progression for CKD are limited. As a consequence, more than 2300 additional Australians need kidney replacement each year and many more die of kidney failure. We have reduced and prevented injury in a mouse model of CKD by administering protective white blood cells - macrophages. This project will modify macrophages ex vivo to optimize them for use as a therapy for CKD.
Phenotypic And Functional Characterisation Of CD4 T Helper 22 Cells And Their Role In The Regulation Of Chronic Allergic Disease Of The Lung And Skin
Funder
National Health and Medical Research Council
Funding Amount
$714,061.00
Summary
Allergic inflammatory diseases such as asthma and allergic dermatitis are major health problems in our community that lead to poor quality of life. These diseases are induced by activation of immune cells known as T helper (Th) lymphocytes. Recently Th22 cells have been identified in patients with allergic diseases. In this study we will, for the first time, characterise these cells and determine their role in the processes that lead to chronic inflammation in asthma and allergic dermatitis.
Enhancing Innate Immune Responses To Influenza In Chronic Obstructive Pulmonary Disease
Funder
National Health and Medical Research Council
Funding Amount
$522,323.00
Summary
Infection with influenza is a serious health problem for all, but particularly those with chronic lung diseases such as chronic obstructive pulmonary disease (COPD). Current treatments are limited. We have previously shown that human COPD airway cells are more susceptible to infection with influenza and the virus is able to effectively block the early immune response. We propose to define the mechanism that underlie this and design novel inhibitors to enhance the early immune response of these c ....Infection with influenza is a serious health problem for all, but particularly those with chronic lung diseases such as chronic obstructive pulmonary disease (COPD). Current treatments are limited. We have previously shown that human COPD airway cells are more susceptible to infection with influenza and the virus is able to effectively block the early immune response. We propose to define the mechanism that underlie this and design novel inhibitors to enhance the early immune response of these cells and reduce the effects of infection.Read moreRead less